As Pfizer Closes Door On Exubera, Has Window Opened For Others?
Pfizer's decision to terminate its Exubera program - the first inhaled insulin product to hit the market - could provide an opportunity for other drug makers looking to step into the market, especially those prepared to address obstacles illuminated by Pfizer
You may also be interested in...
FDA advisory committee review of MannKind’s inhaled insulin revisits safety issues that troubled Pfizer’s first-of-its-kind product, including a potential lung cancer risk and declines in pulmonary function.
Deal terms may show pharma’s faith that Afresa can beat the stigma of Pfizer’s fizzled Exubera.
Despite safer-seeming profile, many skeptical of Afresa after flameout of Pfizer’s product.